Treatment options for rheumatoid arthritis beyond TNF-α inhibitors

References

• Emery P. Treatment of rheumatoid arthritis. Br. Med. J.332, 152–155 (2006).
   PubMed Web of Science ®Google Scholar
• Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin. Exp. Rheumatol.26(5 Suppl. 51), S35–S61 (2008).
   PubMed Web of Science ®Google Scholar
• Sokka T, Haugeberg G, Pincus T. Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective. Clin. Exp. Rheumatol.25(6 Suppl. 47), 86–97 (2007).
   PubMedGoogle Scholar
• Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen J. Methotrexate as the ‘anchor drug’ for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol.21(Suppl. 31), 179–185 (2003).
   Google Scholar
• Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long-term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely due to laboratory abnormalities. Ann. Rheum. Dis.64, 207–211 (2005).
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet364, 263–269 (2004).
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med.146, 406–415 (2007).
   Google Scholar
• Möttönen T, Hannonen P, Leirisalo-Repo M et al.; for the FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet353, 1568–1573 (1999).
   PubMed Web of Science ®Google Scholar
• Yazici Y, Yazici H. Tumor necrosis factor a inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin. Exp. Rheumatol.26, 449–452 (2008).
   Google Scholar
• van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet374(9688), 459–466 (2009).
   Google Scholar
• Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol.27, 907–913 (2009).
   Google Scholar
• Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum.56(1), 13–20 (2007).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistnt active rheumatoid arthritis. Ann. Intern. Med.144, 865–876 (2006).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N. Engl. J. Med.353, 1114–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Westhovens R, Robles M, Ximenes AC et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis.68(12), 1870–1877 (2009).
   PubMed Web of Science ®Google Scholar
• Yazici Y. Treatment of rheumatoid arthritis: we are getting there. Lancet374, 210–221 (2009).
   Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosmowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum.54, 1390–1400 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum.54, 2793–2806 (2006).
   PubMed Web of Science ®Google Scholar
• Tak PP, Rigby WFC, Rubbert-Roth A et al. Rituximab in combination with methotrexate (MTX) significantly inhibits joint damage and improves clinical outcomes in patients with early active RA who are naïve to MTX: a randomized active comparator placebo-controlled trial (IMAGE). Arthritis Rheum.60, S636 (2009).
   Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A et al.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet371, 987–997 (2008).
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis.67(11), 1516–1523 (2008); Erratum in:Ann. Rheum. Dis.68(2), 296 (2009).
   Google Scholar
• Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis.69, 88–96 (2010).
   PubMed Web of Science ®Google Scholar